Key Inclusion Criteria:  Diagnosis of chronic kidney disease, not receiving dialysis, with an eGFR 15-60 mL/min/1.73 m2. Baseline Hb level ≥ 8 g/dL and <10.0 g/dL. No iron deficiency TSAT ≥ 20% and ferritin ≥ 100 ng/mL at screening test Serum folate and vitamin B12 ≥ lower limit of normal at screening test AST and ALT ≤ 3×ULN. Total bilirubin ≤ 1.5×ULN.  Key Exclusion Criteria:  Concurrent retinal neovascular lesions requiring treatment including proliferative diabetic retinopathy, exudative age-related macular degeneration, retinal vein occlusion, macular edema, etc. Concurrent autoimmune disease with inflammatory symptoms that is possibly the principal cause of anemia. History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract or concurrent gastroparesis. Clinically significant bleeding (eg, requiring transfusion or drop in Hb of ≥ 2g/dL) within 4 weeks of first dose; no bleeding diathesis or risk of bleeding that has not been medically or surgically corrected at least 4 weeks prior to first dose of study drug. Uncontrolled hypertension (more than one-third of identifiable diastolic blood pressure values >90 mmHg within 16 weeks prior to and including the screening assessment). Concurrent congestive heart failure (New York Heart Association [NYHA] Class III or higher). History of stroke, transient ischemic attack, myocardial infarction, thromboembolic event, pulmonary embolism, or lung infarction within 24 weeks before the screening assessment. Concurrent anemia due to another cause other than renal anemia Known hemosiderosis, hemochromatosis or hyper-coagulable condition Any treatment with a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) Total bilirubin >1.5xULN, or AST>3xULN, or ALT>3xULN, or ALP>3xULN, or previous or concurrent serious liver disease (acute or active chronic hepatitis, cirrhosis, etc.) thought to be caused by ESAs. Patients that have major surgery planned during the study period. Having undergone blood transfusion and/or a surgical procedure within 8 weeks before the screening assessment. Having undergone a kidney transplantation. History of a seizure disorder or any occurrence of seizures in the past